Global perspective of COVID-19 epidemiology for a full-cycle pandemic
- PMID: 33026101
- PMCID: PMC7646031
- DOI: 10.1111/eci.13423
Global perspective of COVID-19 epidemiology for a full-cycle pandemic
Abstract
As of October 2020, there are >1 million documented deaths with COVID-19. Excess deaths can be caused by both COVID-19 and the measures taken. COVID-19 shows extremely strong risk stratification across age, socioeconomic factors, and clinical factors. Calculation of years-of-life-lost from COVID-19 is methodologically challenging and can yield misleading over-estimates. Many early deaths may have been due to suboptimal management, malfunctional health systems, hydroxychloroquine, sending COVID-19 patients to nursing homes, and nosocomial infections; such deaths are partially avoidable moving forward. About 10% of the global population may be infected by October 2020. Global infection fatality rate is 0.15-0.20% (0.03-0.04% in those <70 years), with large variability across locations with different age-structure, institutionalization rates, socioeconomic inequalities, population-level clinical risk profile, public health measures, and health care. There is debate on whether at least 60% of the global population must be infected for herd immunity, or, conversely, mixing heterogeneity and pre-existing cross-immunity may allow substantially lower thresholds. Simulations are presented with a total of 1.58-8.76 million COVID-19 deaths over 5-years (1/2020-12/2024) globally (0.5-2.9% of total global deaths). The most favorable figures in that range would be feasible if high risk groups can be preferentially protected with lower infection rates than the remaining population. Death toll may also be further affected by potential availability of effective vaccines and treatments, optimal management and measures taken, COVID-19 interplay with influenza and other health problems, reinfection potential, and any chronic COVID-19 consequences. Targeted, precise management of the pandemic and avoiding past mistakes would help minimize mortality.
Keywords: COVID-19; epidemiology; infection fatality rate; mortality; risk factors.
© 2020 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.
Conflict of interest statement
None.
Comment in
-
Letter to the Editor Re: Global perspective of COVID-19 epidemiology for a full-cycle pandemic.Eur J Clin Invest. 2021 Jan;51(1):e13447. doi: 10.1111/eci.13447. Epub 2020 Nov 15. Eur J Clin Invest. 2021. PMID: 33131076 No abstract available.
-
The COVID-19 insidious trick: Subjective perception of numbers.Eur J Clin Invest. 2021 Feb;51(2):e13465. doi: 10.1111/eci.13465. Epub 2020 Dec 8. Eur J Clin Invest. 2021. PMID: 33251590 Free PMC article. No abstract available.
Similar articles
-
Excess years of life lost to COVID-19 and other causes of death by sex, neighbourhood deprivation, and region in England and Wales during 2020: A registry-based study.PLoS Med. 2022 Feb 15;19(2):e1003904. doi: 10.1371/journal.pmed.1003904. eCollection 2022 Feb. PLoS Med. 2022. PMID: 35167587 Free PMC article.
-
Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21.Lancet. 2022 Apr 16;399(10334):1513-1536. doi: 10.1016/S0140-6736(21)02796-3. Epub 2022 Mar 10. Lancet. 2022. PMID: 35279232 Free PMC article.
-
Years of life lost to COVID-19 in 81 countries.Sci Rep. 2021 Feb 18;11(1):3504. doi: 10.1038/s41598-021-83040-3. Sci Rep. 2021. PMID: 33603008 Free PMC article.
-
Flaws and uncertainties in pandemic global excess death calculations.Eur J Clin Invest. 2023 Aug;53(8):e14008. doi: 10.1111/eci.14008. Epub 2023 Apr 24. Eur J Clin Invest. 2023. PMID: 37067255 Free PMC article. Review.
-
Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications.Eur J Epidemiol. 2020 Dec;35(12):1123-1138. doi: 10.1007/s10654-020-00698-1. Epub 2020 Dec 8. Eur J Epidemiol. 2020. PMID: 33289900 Free PMC article.
Cited by
-
Freedom of Choice to Vaccinate and COVID-19 Vaccine Hesitancy in Italy.Vaccines (Basel). 2022 Nov 21;10(11):1973. doi: 10.3390/vaccines10111973. Vaccines (Basel). 2022. PMID: 36423068 Free PMC article.
-
Nebulization of glutathione and N-Acetylcysteine as an adjuvant therapy for COVID-19 onset.Adv Redox Res. 2021 Dec;3:100015. doi: 10.1016/j.arres.2021.100015. Epub 2021 Aug 8. Adv Redox Res. 2021. PMID: 35425932 Free PMC article. Review.
-
An assessment of case-fatality and infection-fatality rates of first and second COVID-19 waves in Italy.Acta Biomed. 2021 Oct 1;92(S6):e2021420. doi: 10.23750/abm.v92iS6.12241. Acta Biomed. 2021. PMID: 34739462 Free PMC article.
-
Antibiotic resistance during and beyond COVID-19.JAC Antimicrob Resist. 2021 Jun 15;3(Suppl 1):i5-i16. doi: 10.1093/jacamr/dlab052. eCollection 2021 Jun. JAC Antimicrob Resist. 2021. PMID: 34223149 Free PMC article.
-
Identifying the Hot Spot Residues of the SARS-CoV-2 Main Protease Using MM-PBSA and Multiple Force Fields.Life (Basel). 2021 Dec 31;12(1):54. doi: 10.3390/life12010054. Life (Basel). 2021. PMID: 35054447 Free PMC article.
References
-
- Spencer E, Jefferson T, Brassey J, Heneghan C. When is covid covid?. https://www.cebm.net/covid‐19/when‐is‐covid‐covid/. Accessed October 4, 2020.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous